Tropomyosin receptor kinase (TRK) fusion-positive gliomas can be targeted with larotrectinib, a highly selective small-molecule inhibitor of TRK fusion positive gliomas [39]. The gene discussed is NTRK1; the disease is central nervous system cancer.